These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1145 related items for PubMed ID: 10459170

  • 1. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS, Starr MS.
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [Abstract] [Full Text] [Related]

  • 2. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
    Biggs CS, Fisher A, Starr MS.
    Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
    [Abstract] [Full Text] [Related]

  • 3. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA.
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [Abstract] [Full Text] [Related]

  • 4. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent.
    Fisher A, Biggs CS, Eradiri O, Starr MS.
    Neuroscience; 2000 Mar; 95(1):97-111. PubMed ID: 10619466
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H, Aimi Y, Nagatsu I, Taki K, Kudo M, Arai R.
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [Abstract] [Full Text] [Related]

  • 6. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM, García-Horsman JA, Piltonen M, Huotari M, Männistö PT.
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [Abstract] [Full Text] [Related]

  • 7. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
    Gołembiowska K, Dziubina A.
    Neuropharmacology; 2004 Sep; 47(3):414-26. PubMed ID: 15275831
    [Abstract] [Full Text] [Related]

  • 8. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK, Keyghobadi M, Moore C, Meshul CK.
    Neuroscience; 2005 Sep; 136(1):333-41. PubMed ID: 16198485
    [Abstract] [Full Text] [Related]

  • 9. Pentobarbital inhibits L-DOPA-induced dopamine increases in the rat striatum: An in vivo microdialysis study.
    Adachi YU, Yamada S, Satomoto M, Watanabe K, Higuchi H, Kazama T, Doi M, Sato S.
    Brain Res Bull; 2006 May 15; 69(5):593-6. PubMed ID: 16647588
    [Abstract] [Full Text] [Related]

  • 10. Rotenone increases glutamate-induced dopamine release but does not affect hydroxyl-free radical formation in rat striatum.
    Leng A, Feldon J, Ferger B.
    Synapse; 2003 Dec 01; 50(3):240-50. PubMed ID: 14515342
    [Abstract] [Full Text] [Related]

  • 11. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
    Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, Klitgaard H, Bioulac B, Gross CE, Bezard E, Boraud T.
    Neurobiol Dis; 2006 Jun 01; 22(3):586-98. PubMed ID: 16531050
    [Abstract] [Full Text] [Related]

  • 12. NMDA receptor antagonists increase the release of dopamine in the substantia nigra of reserpine-treated rats.
    Biggs CS, Fowler LJ, Whitton PS, Starr MS.
    Eur J Pharmacol; 1996 Mar 28; 299(1-3):83-91. PubMed ID: 8901010
    [Abstract] [Full Text] [Related]

  • 13. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
    Jonkers N, Sarre S, Ebinger G, Michotte Y.
    Eur J Pharmacol; 2000 Nov 03; 407(3):281-91. PubMed ID: 11068024
    [Abstract] [Full Text] [Related]

  • 14. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra.
    Yamamoto BK, Nash JF, Gudelsky GA.
    J Pharmacol Exp Ther; 1995 Jun 03; 273(3):1063-70. PubMed ID: 7791076
    [Abstract] [Full Text] [Related]

  • 15. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
    Sarre S, Lanza M, Makovec F, Artusi R, Caselli G, Michotte Y.
    Eur J Pharmacol; 2008 Apr 28; 584(2-3):297-305. PubMed ID: 18342306
    [Abstract] [Full Text] [Related]

  • 16. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K, Voehringer P, Ferger B.
    J Neurochem; 2010 Jan 28; 112(2):444-52. PubMed ID: 19895663
    [Abstract] [Full Text] [Related]

  • 17. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
    Izurieta-Sánchez P, Sarre S, Ebinger G, Michotte Y.
    Eur J Pharmacol; 2000 Jul 07; 399(2-3):151-60. PubMed ID: 10884514
    [Abstract] [Full Text] [Related]

  • 18. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK.
    J Pharmacol Exp Ther; 1997 Jan 07; 280(1):393-401. PubMed ID: 8996220
    [Abstract] [Full Text] [Related]

  • 19. Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study.
    Yang J, Hu LF, Liu X, Zhou F, Ding JH, Hu G.
    Life Sci; 2006 Mar 20; 78(17):1940-4. PubMed ID: 16216278
    [Abstract] [Full Text] [Related]

  • 20. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N, Shintani-Mizushima A, Kakishita K, Itakura T.
    Exp Neurol; 2004 Jul 20; 188(1):65-73. PubMed ID: 15191803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.